At the news
? BEARISHIMPACT 7/10 PRESS-RELEASE filed Apr 17, 2026 at 16:02 ET
Revolution Medicines raised approximately $2.225 billion through a concurrent public offering of common stock and convertible notes, with net proceeds of $2.137 billion. The capital raise includes 12.15 million shares at $142 per share and $500 million in 0.50% convertible senior notes due 2033, marking a significant dilutive financing event. The funds will support R&D and commercialization efforts for its RAS-addicted cancer therapies.
- Closed concurrent public offerings: 12,147,887 shares of common stock at $142/share and $500 million in 0.50% convertible senior notes due 2033
- Gross proceeds: $2.225 billion; net proceeds: $2.137 billion after underwriting discounts and expenses
- Convertible notes have a 0.50% coupon, mature May 1, 2033, and initial conversion price of $198.80 per share (40% premium to stock offering price)
- Proceeds to be used for R&D, potential commercialization, G&A, and capital expenditures
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access